| Bioactivity | NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects by inhibiting the activation of NLRP3 inflammasome without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model[1]. |
| Invitro | NLRP3-IN-45 (0.2-5 μM，1 h) 在 BMDMs 细胞中可抑制 NLRP3 炎症小体的激活，且不影响 AIM2 和 NLRC4 炎症小体的激活[1]。NLRP3-IN-45 (0.2-5 μM，1 h) 不影响 NLRP3 炎症小体激活的启动阶段[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> NLRP3-IN-45 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | NLRP3-IN-45 (0.1-10 mg/kg，一天一次，3天) 在急性肺损伤小鼠模型中抑制 NLRP3 炎性体的激活，对急性肺损伤有保护作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C27H30FNO6 |
| Molar Mass | 483.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mengting Li, et al. Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury. Eur J Med Chem |